LOAMU
PACB icon

Lombard Odier Asset Management (USA)’s Pacific Biosciences PACB Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,000
Closed -$1.03M – 274
2017
Q1 		$1.03M Buy
+2,000
New +$9.79K 0.1% 167

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s PACB Position: Q1 2025 in Review

Lombard Odier Asset Management (USA) sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 31,819 shares — an estimated $58.2K sold.

Lombard Odier Asset Management (USA) first reported a position in PACB in Q3 2016 and held it in 11 quarters. The position peaked at $4.33M in Q3 2018. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

  • Lombard Odier Asset Management (USA) reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 31,819 Pacific Biosciences shares in Q1 2025, an estimated $58.2K.
  • Lombard Odier Asset Management (USA) first reported a position in Pacific Biosciences in Q3 2016 and held it in 11 quarters.
  • Lombard Odier Asset Management (USA)'s Pacific Biosciences position peaked at $4.33M in Q3 2018.
  • 225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q1 2025, filed 15 May 2025.